Showing 85,221 - 85,240 results of 85,858 for search '(progres OR programs)', query time: 0.40s Refine Results
  1. 85221
  2. 85222

    Evidence-based prevention and management of febrile neutropenia in patients undergoing chemotherapy for breast cancer (基于循证的乳腺癌化疗患者粒细胞减少性发热的预防与管理)... by BIAN Guanyue (边关月), CHEN Qian (陈茜), SUN Ling (孙玲)

    Published 2021-08-01
    “…Conclusion The evidence-based quality review program has significantly improved nursing practice in the prevention and management of febrile neutropenia in breast cancer patients undergoing chemotherapy, but it still needs to be reviewed and improved to improve the quality of nursing. …”
    Get full text
    Article
  3. 85223

    Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection: an exploratory post-hoc analysis of the BALANCE randomised clinical trialResearch in... by Sean W.X. Ong, Ruxandra Pinto, Asgar Rishu, Steven Y.C. Tong, Robert J. Commons, John M. Conly, Gerald A. Evans, Michael Fralick, Christopher Kandel, Philippe R.S. Lagacé-Wiens, Todd C. Lee, Sylvain A. Lother, Derek R. MacFadden, John C. Marshall, Valérie Martel-Laferrière, Michael Mayette, Emily G. McDonald, John D. Neary, Josef Prazak, Edward Raby, Adrian Regli, Benjamin A. Rogers, Stephanie Smith, Linda R. Taggart, Han Ting Wang, Terence Wuerz, Dafna Yahav, Paul J. Young, Robert A. Fowler, Nick Daneman, Nick Daneman, Asgar Rishu, Ruxandra Pinto, Benjamin Rogers, Yahya Shehabi, Rachael Parke, Deborah J. Cook, Yaseen Arabi, John Muscedere, Steven Reynolds, Richard Hall, Dhiraj Bhatia Dwivedi, Colin McArthur, Shay McGuinness, Dafna Yahav, Bryan Coburn, Anna Geagea, Pavani Das, Phillip Shin, Michael Detsky, Andrew Morris, Michael Fralick, Jeff E. Powis, Christopher Kandel, Wendy Sligl, Sean M. Bagshaw, Nishma Singhal, Emilie Belley-Cote, Richard Whitlock, Kosar Khwaja, Susan Morpeth, Alex Kazemi, Tony Williams, Derek R. MacFadden, Lauralyn McIntyre, Jennifer L.Y. Tsang, Francois Lamontagne, Alex Carignan, John Marshall, Jan O. Friedrich, Robert Cirone, Mark Downing, Christopher Graham, Joshua Davis, Erick Duan, John Neary, Gerald Evans, Basem Alraddadi, Sameera Al Johani, Claudio Martin, Sameer Elsayed, Ian Ball, François Lauzier, Alexis F. Turgeon, Henry Thomas Stelfox, John Conly, Todd C. Lee, Emily G. McDonald, Richard Sullivan, Jennifer Grant, Ilya Kagan, Paul Young, Cassie Lawrence, Kevin O'Callaghan, Matthew Eustace, Keat Choong, Pierre Aslanian, Ulrike Buehner, Tom Havey, Alexandra Binnie, Josef Prazak, Brenda Reeve, Edward Litton, Sylvain Lother, Anand Kumar, Ryan Zarychanski, Tomer Hoffman, David L. Paterson, Peter Daley, Robert J. Commons, Emmanuel Charbonney, Jean-Francois Naud, Sally Roberts, Ravindranath Tiruvoipati, Sachin Gupta, Gordon Wood, Omar Shum, Spiros Miyakis, Peter Dodek, Clement Kwok, Linda R. Taggart, Stephanie Smith, Karen Doucette, Robert A. Fowler

    Published 2025-05-01
    “…VML is supported by Clinical Research Scholar—Junior 2 program (FRQ-S).…”
    Get full text
    Article
  4. 85224

    Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v by Ulrich Moebius, Radek Špíšek, David Béchard, Zuzana Antosova, Nada Podzimkova, Irena Adkins, Klara Danova, Ekaterina Simonova, Katerina Behalova, Petr Danek, Matej Fabisik, Kamila Hladikova, Lucie Kosinova, Pavel Marasek, Vladyslav Mazhara, Katerina Sajnerova, Milada Sirova, Marek Kovar, Martin Steegmaier, Hana Matuskova, Iva Malatova, Klara Hrabankova, Denise Greco, Ondrej Martinec, Romana Mikyskova, Milan Reinis, Lenka Palova Jelinkova

    Published 2025-04-01
    “…Background SOT201 and its murine surrogate mSOT201 are novel cis-acting immunocytokines consisting of a humanized/murinized/, Fc-silenced anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) fused to an attenuated human interleukin (IL)-15 and the IL-15Rα sushi+ domain. …”
    Get full text
    Article
  5. 85225

    Echocardiographic evaluation of myocardial structural and functional changes in patients with stage 5 chronic kidney disease before and after kidney transplantation by M. Sh. Khubutiya, E. V. Shuvalova, O. N. Rzhevskaya, L. T. Khamidova, A. A. Ivannikov, Kh. G. Alidzhanova, A. G. Balkarov, I. V. Dmitriev

    Published 2024-03-01
    “…A retrospective cross-sectional study included 111 individuals of whom 36 patients underwent evaluation for kidney transplant waiting list placement program (Group I), and 51 patients received kidney transplants from deceased donors (Group II). …”
    Get full text
    Article
  6. 85226

    Possibilities of rehabilitation of the psychological state of children over 10 years old, suffering from acute respiratory diseases, in conditions of war in Ukraine by I.O. Mityuryayeva-Kornijko, Ie.A. Burlaka, T.D. Klets, O.A. Panchenko, A.V. Kabantseva, R.V. Terletskiy

    Published 2025-03-01
    “…The study was carried out as part of the program of outpatient observation of children with various acute manifestations of acute respiratory infections against the background of stress damage to the nervous system due to the war in Ukraine. …”
    Get full text
    Article
  7. 85227

    Evaluation of Immunogenicity of Inactivated Whole-Virion Booster Vaccine against SARS-CoV-2 in a phase I, II Clinical Trial by I. O. Stoma, E. V. Voropaev, E. I. Mikhailova, K. S. Korsak, O. V. Osipkina, A. V. Molchanova, A. A. Kovalev, D. M. Los, A. A. Ziatskov, A. S. Shaforost, M. N. Yatsuk, A. Yu. Braga, N. V. Trofimova, A. M. Dronina, E. L. Gasich, V. A. Gorbunov, A. Ev. Hancharou

    Published 2025-01-01
    “…Statistical processing of the data was performed using the R programming language.Results. The values of fold change in IgG concentration to SARS-CoV-2 on day 42 and 90 in subjects who received «BelCovidVac» vaccine were significantly higher than those of subjects who received placebo (p=0,05, p=0,02, respectively). …”
    Get full text
    Article
  8. 85228

    Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation by Pengyu Wang, Weihua Guo, Shuyue Liu, Shouyi Li, Jiaqi Li, Bowen Ding, Fengyi Yin, Yang Yang, Xingjiang Li, Pei Cao, Chaozhe Ma, Wanying Zhang, Yidan Song, Yating Geng, Lantao Liu, Jing Hu, Jihui Hao, Yukuan Feng

    Published 2025-05-01
    “…Recent studies have highlighted the critical role of intratumoral copper levels in regulating the expression of programmed cell death ligand-1 (PD-L1), suggesting that copper-induced cuproptosis not only enhances cancer cell death but may also amplify the effects of anti-PD-L1 antibodies (αPD-L1). …”
    Get full text
    Article
  9. 85229
  10. 85230

    Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy by Ke Xu, Qingfeng Zhu, Suzanne L Topalian, Robert A Anders, Janis M Taube, Mark Yarchoan, Keziban Ünsal-Kaçmaz, Logan L Engle, Tracee L McMiller, Sepideh Besharati, Junghwa Lee, Feriyl Bhaijee, Alan E Berger

    Published 2024-11-01
    “…Background Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. …”
    Get full text
    Article
  11. 85231

    Development, validation, and clinical application of a machine learning model for risk stratification and management of cervical cancer screening based on full-genotyping hrHPV tes... by Binhua Dong, Zhen Lu, Tianjie Yang, Junfeng Wang, Yan Zhang, Xunyuan Tuo, Juntao Wang, Shaomei Lin, Hongning Cai, Huan Cheng, Xiaoli Cao, Xinxin Huang, Zheng Zheng, Chong Miao, Yue Wang, Huifeng Xue, Shuxia Xu, Xianhua Liu, Huachun Zou, Pengming Sun

    Published 2025-02-01
    “…Funding: National Natural Science Foundation of China; Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China; Fujian Province Central Government-Guided Local Science and Technology Development Project; Fujian Province's Third Batch of Flexible Introduction of High-Level Medical Talent Teams; Fujian Provincial Natural Science Foundation of China; Fujian Provincial Science and Technology Innovation Joint Fund.…”
    Get full text
    Article
  12. 85232

    First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis by Lijuan Chen, Lijuan Chen, Jie Liu, Jie Liu, Junfeng Lu, Junfeng Lu, Xiufeng Hu, Xiufeng Hu, Erjing An, Erjing An, Yanqiu Zhao, Yanqiu Zhao

    Published 2025-06-01
    “…ObjectiveTo evaluate the optimal first-line treatment options for programmed death-ligand 1 (PD-L1) negative lung adenocarcinoma (LUAD) patients without common gene-alterations.MethodsA total of 159 PD-L1-negative LUAD patients without common gene-alterations were included. …”
    Get full text
    Article
  13. 85233

    Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab by Amit Gupta, Pingfu Fu, Nathan A Pennell, Mohamed Gad, Mohammadhadi Khorrami, Anant Madabhushi, Anas Saad, Pradnya Patil, Khalid Jazieh, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey

    Published 2022-03-01
    “…In clinical practice in the USA, durvalumab continues to be used in patients across all levels of programmed cell death ligand-1 (PD-L1) expression. While immune therapies have shown promise in several cancers, some patients either do not respond to the therapy or have cancer recurrence after an initial response. …”
    Get full text
    Article
  14. 85234

    AI-based pelvic floor surface electromyography reference ranges and high-precision pelvic floor dysfunction diagnosisResearch in context by Juan Chen, Jiahui Yao, Wei Chen, Feng Zhang, Heyuan Wang, Xiaoying Xu, Huan Ge, Hongmei Zhou, Jin Cen, Dan Li, Bengui Jiang, Li He, Tingting Fu, Zhengxian Xu, Lei Chu, Shuxia Zhang, Dongmei Yao, Linyi Wei, Liu Huang, Anjing Ge, Cuiping Jin, Zimu Fu, Qin Liu, Xuefeng Yu, Chengmao Zhao, Tengjiao Wang, Lan Zhu

    Published 2025-07-01
    “…Funding: This study was supported by grants from the National Key R&D Program of China: The Establishment of a Comprehensive Network for PFD Prevention, Rehabilitation, Pelvic Floor Surgery and Related Complications (2021YFC2701300), Perception and Analysis of the Situation of Major Infectious Disease Outbreaks Based on Internet Big Data (2021ZD0111202), Research on New Models for Forecasting Major Infectious Diseases and Policy Evaluation (2021ZD0111205); Beijing Natural Science Foundation (7212073), National High-Level Hospital Clinical Research Funding (2022-PUMCH-B-087) and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M- C&T-B- 021).…”
    Get full text
    Article
  15. 85235

    The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-worl... by Baoyue Pan, He Huang, Ting Wan, Qidan Huang, Shanyang He, Shijie Xu, Siyu Chen, Jiaxin Yin, Jundong Li, Min Zheng

    Published 2025-06-01
    “…However, the efficacy of cadonilimab in patients with prior failure of anti- programmed death receptor-1 (PD-1) inhibitors, as well as a direct comparison of its efficacy and safety with anti-PD-1 inhibitors, has not been reported in real-world settings.MethodsWe conducted a retrospective study at our hospital, including two R/M CC patient cohorts. …”
    Get full text
    Article
  16. 85236
  17. 85237
  18. 85238
  19. 85239
  20. 85240